VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed on the Frankfurt Stock Exchange (FSE) under the ticker symbol "7J0”.
This strategic milestone marks Rakovina Therapeutics' entry into one of the largest equity markets in Europe, providing increased visibility and accessibility to European and global investors. The Frankfurt Stock Exchange listing complements the company's existing listing on the TSX Venture Exchange (TSX-V: RKV), enabling broader participation in Rakovina Therapeutics' mission to revolutionize cancer drug discovery.
Global Reach and Accessibility
Rakovina's listing on the Frankfurt Stock Exchange is expected to enhance its presence in Europe and attract new investors from one of the world's most active trading hubs. With the FSE listing, the company aims to build awareness of its unique approach to drug discovery, leveraging its AI-driven Deep Docking™ and Variational AI collaborations to identify and develop novel drug candidates targeting DNA-damage response (DDR) mechanisms-key vulnerabilities in many aggressive cancers.
Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics, commented: "We are excited to engage with a broader audience through our listing on the Frankfurt Stock Exchange. This milestone aligns with our strategy to increase international visibility and establish Rakovina as a leading innovator in oncology drug discovery. The Frankfurt Exchange listing will enhance liquidity and provide European investors an opportunity to participate in our mission to advance life-saving cancer treatments.”
Advancing Innovation in Oncology
Rakovina Therapeutics leverages exclusive access to AI platforms such as Deep Docking™ and Variational AI through strategic partnerships to screen DNA-damage response (DDR) compounds, accelerating the identification of promising drug candidates. The global DDR therapy market, projected to reach $18 billion annually by 2030, highlights the transformative potential of Rakovina's innovative approach to drug discovery and development.
The company's Frankfurt Exchange listing further solidifies its commitment to creating long-term value for shareholders while accelerating the development of innovative cancer therapies.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Further information may be found at www.rakovinatherapeutics.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans,” "is expected,” "expects,” "scheduled,” "intends,” "contemplates,” "anticipates,” "believes,” "proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may,” "could,” "would,” "might,” or "will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at www.sedar.com.
For Further Information Contact:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
778-773-5432
